Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals Abstract #1231

Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Aim(s): To raise awareness of the burden of NETs on pts’ daily lives by tumor location.
Materials and methods: Anonymous survey of NET pts from >12 countries conducted by INCA/Novartis in 2014 (Americas, Asia, Europe, Oceania) on the NET pt experience, including impact of NETs on pts’ lives. All comparisons are significant at the P<0.05 level. This NET patient survey was a collaboration between INCA and Novartis and the survey was funded by Novartis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden

To read results and conclusion, please login ...

Further abstracts you may be interested in

#259 Risk of Cardiovascular Events (CV) in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NETs are malignant neoplasms capable of systemic hormone production. Oversecretion of hormones can result in many different symptoms, including CV events such as CAD, valvular disease and stroke.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Chen C C, Liu Z M, Hess G P, Yao J C, ...
#1767 International Patient Survey of Physical, Emotional and Informational Challenges when Living with NETs: Understanding the Unmet Needs
Introduction: The usefulness of information sources used by NET patients is rarely explored by patient surveys of disease burden/impact on daily living, and may be key to optimizing care.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Khan M, Majdi A, Goldstein G, Mellar K, ...
#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)
Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Research Prof Kimberly Webster
#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: RN Gladys Grance
#1217 The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life